' 
SCIENTIFIC SCORE
Possibly Effective
Based on 11 Researches
7.6
USERS' SCORE
Good
Based on 1 Review
8.5
Supplement Facts
Serving Size: 1 Tablet
Amount Per Serving
%DV
Folate
1,360 mcg DFE** (800 mcg folic acid)
340%
Vitamin B-12 (as Cyanocobalamin)
25 mcg
1042%
Top Medical Research Studies
8
Vitamin B12 may treat arthritis
Vitamin B12 inhibits peptidylarginine deiminases and ameliorates rheumatoid arthritis in CAIA mice.
High relevance to rheumatoid arthritis
We explored the impact of vitamin B12 on rheumatoid arthritis, focusing on its ability to inhibit a specific enzyme known as PADI-4, which plays a key role in the disease's progression. Our findings suggest that vitamin B12 preferentially targets PADI-4 compared to another similar enzyme, PADI-2. This inhibition corresponds with a significant reduction in overall citrullination levels in cells, including histone H3 citrullination, which is relevant to the condition.
In our experiment, we utilized a specific model of arthritis in mice, known as collagen type II antibody-induced arthritis (CAIA). We administered hydroxocobalamin, a form of vitamin B12, and observed a marked improvement in the severity of arthritis symptoms in these mice. Moreover, the treatment led to a decrease in the expression of various inflammatory factors and cytokines associated with rheumatoid arthritis, such as IL17A, TNFα, and IL-6, as well as PADI-4 itself.
These findings indicate that vitamin B12 might represent a promising avenue for treating rheumatoid arthritis and warrant further investigation.
In our experiment, we utilized a specific model of arthritis in mice, known as collagen type II antibody-induced arthritis (CAIA). We administered hydroxocobalamin, a form of vitamin B12, and observed a marked improvement in the severity of arthritis symptoms in these mice. Moreover, the treatment led to a decrease in the expression of various inflammatory factors and cytokines associated with rheumatoid arthritis, such as IL17A, TNFα, and IL-6, as well as PADI-4 itself.
These findings indicate that vitamin B12 might represent a promising avenue for treating rheumatoid arthritis and warrant further investigation.
Read More
9
Folic acid-modified vesicles tackle RA
Folic acid-modified ginger-derived extracellular vesicles for targeted treatment of rheumatoid arthritis by remodeling immune microenvironment via the PI3K-AKT pathway.
Emphasizes innovative treatment approach
This study presents an innovative approach to tackling rheumatoid arthritis (RA) using folic acid-modified ginger-derived extracellular vesicles (FA-GDEVs). We explored how these tiny vesicles, enriched with bioactive compounds from ginger, can be directed toward inflamed joints by utilizing folic acid to target specific immune cells.
Initially, we investigated the ability of FA-GDEVs to shift the balance of macrophages from the harmful M1 type, which fuels inflammation, to the more healing M2 type. Our findings revealed that FA-GDEVs effectively influence this transition by activating related pathways within the cells.
In practical terms, this means that FA-GDEVs can not only find their way to affected areas more efficiently but also work to reduce signs of RA while maintaining a good safety profile. Ultimately, these ginger-derived vesicles could be a more affordable and safer option for RA treatment, marking a significant advancement in how we approach this chronic condition.
Initially, we investigated the ability of FA-GDEVs to shift the balance of macrophages from the harmful M1 type, which fuels inflammation, to the more healing M2 type. Our findings revealed that FA-GDEVs effectively influence this transition by activating related pathways within the cells.
In practical terms, this means that FA-GDEVs can not only find their way to affected areas more efficiently but also work to reduce signs of RA while maintaining a good safety profile. Ultimately, these ginger-derived vesicles could be a more affordable and safer option for RA treatment, marking a significant advancement in how we approach this chronic condition.
Read More
9
Genetic factors enhance MTX efficacy
The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients.
Study highlights genetic influence
We observed that rheumatoid arthritis (RA) can vary greatly in how patients respond to methotrexate (MTX), a common treatment. Our study focused on understanding how certain genetic variations in the folate pathway could influence this response.
We examined 100 RA patients receiving MTX monotherapy and measured their disease activity both before treatment and after six months. We categorized the patients into those who responded well to the treatment and those who did not, ultimately aiming to find connections between specific genetic variants and treatment outcomes.
We found that patients with the RFC-1 G80A 80AA genotype and those with 2R/3R or 3R/3R genotypes in the TYMS 2R/3R variant showed a better response to MTX therapy. This suggests a potential link between these genetic factors and treatment effectiveness.
While MTX remains the gold standard for treating RA, it’s important to recognize that about 40% of patients may not respond adequately. By identifying genetic markers that could predict response to treatment, we can better tailor therapies in the future and improve patient outcomes.
We examined 100 RA patients receiving MTX monotherapy and measured their disease activity both before treatment and after six months. We categorized the patients into those who responded well to the treatment and those who did not, ultimately aiming to find connections between specific genetic variants and treatment outcomes.
We found that patients with the RFC-1 G80A 80AA genotype and those with 2R/3R or 3R/3R genotypes in the TYMS 2R/3R variant showed a better response to MTX therapy. This suggests a potential link between these genetic factors and treatment effectiveness.
While MTX remains the gold standard for treating RA, it’s important to recognize that about 40% of patients may not respond adequately. By identifying genetic markers that could predict response to treatment, we can better tailor therapies in the future and improve patient outcomes.
Read More
Most Useful Reviews
8.8
Needed product
I require this product for my rheumatoid arthritis and have always been satisfied with selections from NOW company.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 11 Researches
7.6
- All Researches
9
Folic acid-modified vesicles tackle RA
Folic acid-modified ginger-derived extracellular vesicles for targeted treatment of rheumatoid arthritis by remodeling immune microenvironment via the PI3K-AKT pathway.
Emphasizes innovative treatment approach
This study presents an innovative approach to tackling rheumatoid arthritis (RA) using folic acid-modified ginger-derived extracellular vesicles (FA-GDEVs). We explored how these tiny vesicles, enriched with bioactive compounds from ginger, can be directed toward inflamed joints by utilizing folic acid to target specific immune cells.
Initially, we investigated the ability of FA-GDEVs to shift the balance of macrophages from the harmful M1 type, which fuels inflammation, to the more healing M2 type. Our findings revealed that FA-GDEVs effectively influence this transition by activating related pathways within the cells.
In practical terms, this means that FA-GDEVs can not only find their way to affected areas more efficiently but also work to reduce signs of RA while maintaining a good safety profile. Ultimately, these ginger-derived vesicles could be a more affordable and safer option for RA treatment, marking a significant advancement in how we approach this chronic condition.
Initially, we investigated the ability of FA-GDEVs to shift the balance of macrophages from the harmful M1 type, which fuels inflammation, to the more healing M2 type. Our findings revealed that FA-GDEVs effectively influence this transition by activating related pathways within the cells.
In practical terms, this means that FA-GDEVs can not only find their way to affected areas more efficiently but also work to reduce signs of RA while maintaining a good safety profile. Ultimately, these ginger-derived vesicles could be a more affordable and safer option for RA treatment, marking a significant advancement in how we approach this chronic condition.
Read More
9
Exploring innovative RA treatment
Targeted Macrophage Re-Programming: Synergistic Therapy With Methotrexate and RELA siRNA Folate-Liposome in RAW264.7 Cells and Arthritic Rats.
Considerable effectiveness noted
We explored a new approach to treat rheumatoid arthritis by utilizing a combination of methotrexate and RELA siRNA delivered through folate-liposomes. This innovative method aims to target specific immune cells, namely macrophages, to alter their behavior and reduce inflammation indirectly.
In our investigations, we observed that this treatment significantly diminished inflammation in joint tissues and enhanced mobility in rat models of collagen-induced arthritis. By focusing on the NF-κB pathway, we found that the therapy effectively lowered levels of inflammatory markers like rheumatoid factor and C-reactive protein.
However, it’s worth noting that while folate plays an important role in this innovative delivery system, it’s challenging to pinpoint how much of the treatment's success can be attributed solely to folate itself. Overall, this study highlights exciting possibilities in managing rheumatoid arthritis while addressing the need for improved drug delivery and sustained therapeutic effects.
In our investigations, we observed that this treatment significantly diminished inflammation in joint tissues and enhanced mobility in rat models of collagen-induced arthritis. By focusing on the NF-κB pathway, we found that the therapy effectively lowered levels of inflammatory markers like rheumatoid factor and C-reactive protein.
However, it’s worth noting that while folate plays an important role in this innovative delivery system, it’s challenging to pinpoint how much of the treatment's success can be attributed solely to folate itself. Overall, this study highlights exciting possibilities in managing rheumatoid arthritis while addressing the need for improved drug delivery and sustained therapeutic effects.
Read More
9
Genetic factors enhance MTX efficacy
The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients.
Study highlights genetic influence
We observed that rheumatoid arthritis (RA) can vary greatly in how patients respond to methotrexate (MTX), a common treatment. Our study focused on understanding how certain genetic variations in the folate pathway could influence this response.
We examined 100 RA patients receiving MTX monotherapy and measured their disease activity both before treatment and after six months. We categorized the patients into those who responded well to the treatment and those who did not, ultimately aiming to find connections between specific genetic variants and treatment outcomes.
We found that patients with the RFC-1 G80A 80AA genotype and those with 2R/3R or 3R/3R genotypes in the TYMS 2R/3R variant showed a better response to MTX therapy. This suggests a potential link between these genetic factors and treatment effectiveness.
While MTX remains the gold standard for treating RA, it’s important to recognize that about 40% of patients may not respond adequately. By identifying genetic markers that could predict response to treatment, we can better tailor therapies in the future and improve patient outcomes.
We examined 100 RA patients receiving MTX monotherapy and measured their disease activity both before treatment and after six months. We categorized the patients into those who responded well to the treatment and those who did not, ultimately aiming to find connections between specific genetic variants and treatment outcomes.
We found that patients with the RFC-1 G80A 80AA genotype and those with 2R/3R or 3R/3R genotypes in the TYMS 2R/3R variant showed a better response to MTX therapy. This suggests a potential link between these genetic factors and treatment effectiveness.
While MTX remains the gold standard for treating RA, it’s important to recognize that about 40% of patients may not respond adequately. By identifying genetic markers that could predict response to treatment, we can better tailor therapies in the future and improve patient outcomes.
Read More
9
Nanocomposite shows promise for RA
Therapeutic Potential of Zeolites/Vitamin B12 Nanocomposite on Complete Freund's Adjuvant-Induced Arthritis as a Bone Disorder: In Vivo Study and Bio-Molecular Investigations.
Incorporation complexity limits isolation
We investigated the effectiveness of a novel nanocomposite made from zeolites and Vitamin B12 in treating rheumatoid arthritis, specifically in a rat model induced by complete Freund's adjuvant (CFA). This study aimed to understand how this unique formulation affects the symptoms and underlying processes of the disease.
Our findings revealed that the zeolite/Vitamin B12 combination showed significant improvements in several areas. Notably, it helped alleviate inflammation and oxidative stress common in rheumatoid arthritis. We observed marked reductions in certain inflammatory markers and improved antioxidant levels in the treated rats. This composite seemed to enhance the overall healing of joint tissues as well, which is critical for those suffering from the debilitating effects of this autoimmune disease.
Importantly, while the zeolite/Vitamin B12 nanocomposite demonstrated promising anti-arthritic and antioxidant properties, attributing the effectiveness solely to Vitamin B12 is complicated because it was part of a composite formulation. Thus, while the study suggests potential for future research, it doesn't allow us to isolate the benefits of Vitamin B12 alone for rheumatoid arthritis.
Our findings revealed that the zeolite/Vitamin B12 combination showed significant improvements in several areas. Notably, it helped alleviate inflammation and oxidative stress common in rheumatoid arthritis. We observed marked reductions in certain inflammatory markers and improved antioxidant levels in the treated rats. This composite seemed to enhance the overall healing of joint tissues as well, which is critical for those suffering from the debilitating effects of this autoimmune disease.
Importantly, while the zeolite/Vitamin B12 nanocomposite demonstrated promising anti-arthritic and antioxidant properties, attributing the effectiveness solely to Vitamin B12 is complicated because it was part of a composite formulation. Thus, while the study suggests potential for future research, it doesn't allow us to isolate the benefits of Vitamin B12 alone for rheumatoid arthritis.
Read More
9
Vitamin B12's potential in arthritis
A Novel Hydroxyapatite/Vitamin B Nanoformula for Treatment of Bone Damage: Preparation, Characterization, and Anti-Arthritic, Anti-Inflammatory, and Antioxidant Activities in Chemically Induced Arthritic Rats.
Moderate relevance due to combination effects
We explored the efficacy of a novel nanoformula combining hydroxyapatite and vitamin B12 in treating rheumatoid arthritis in rats induced by Complete Freund's adjuvant. Our research aimed to see if this new treatment could improve conditions associated with arthritis, such as inflammation, joint damage, and oxidative stress.
Through careful preparation and characterization, we created stable nanoparticles that boosted the delivery of vitamin B12. We observed that treated rats had reduced levels of harmful markers typically elevated in arthritis, such as RF and CRP, along with various inflammatory cytokines. Meanwhile, beneficial factors like IL-4 and antioxidant levels increased, suggesting an overall improvement in their condition.
Histopathological analyses showed promising results, indicating less inflammation and damage in the joints of the treated rats compared to untreated ones. We noted improvements in joint injury markers, including reduced inflammatory cell presence, cartilage integrity, and bone condition.
While our findings highlight significant anti-arthritic, antioxidant, and anti-inflammatory effects of this unique vitamin B12 nanoformula, the complexity of the combination makes it hard to isolate the specific role of vitamin B12 alone. Nonetheless, we feel this research opens exciting pathways for developing new treatments for rheumatoid arthritis.
Through careful preparation and characterization, we created stable nanoparticles that boosted the delivery of vitamin B12. We observed that treated rats had reduced levels of harmful markers typically elevated in arthritis, such as RF and CRP, along with various inflammatory cytokines. Meanwhile, beneficial factors like IL-4 and antioxidant levels increased, suggesting an overall improvement in their condition.
Histopathological analyses showed promising results, indicating less inflammation and damage in the joints of the treated rats compared to untreated ones. We noted improvements in joint injury markers, including reduced inflammatory cell presence, cartilage integrity, and bone condition.
While our findings highlight significant anti-arthritic, antioxidant, and anti-inflammatory effects of this unique vitamin B12 nanoformula, the complexity of the combination makes it hard to isolate the specific role of vitamin B12 alone. Nonetheless, we feel this research opens exciting pathways for developing new treatments for rheumatoid arthritis.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
8.8
Needed product
I require this product for my rheumatoid arthritis and have always been satisfied with selections from NOW company.
